FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giroux, V.
Right arrow Articles by Dagorn, J.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giroux, V.
Right arrow Articles by Dagorn, J.-C.
(The FASEB Journal. 2006;20:1982-1991.)
© 2006 FASEB

Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance

Valentin Giroux, Juan Iovanna and Jean-Charles Dagorn1

INSERM U624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, Marseille, France

1Correspondence: Centre de Recherche INSERM, Unité 624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, case 915, 13288 Marseille Cedex 9, France. E-mail: dagorn{at}marseille.inserm.fr

Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of specific kinases in such resistance is likely. We developed a systematic strategy to screen the human kinome and select kinases whose inhibition in pancreatic cancer cells can increase 1) spontaneous apoptosis or 2) gemcitabine-induced apoptosis. The pancreatic adenocarcinoma cell line MiaPaCa-2 was transfected with 645 pairs of siRNAs directed to all human kinases. The same experiment was conducted in cells treated with 150 µM gemcitabine. Apoptosis was measured after 2 days and the results were normalized for cell viability. A panel of 56 kinases whose inhibition increased spontaneous apoptosis by at least 50% was established. Ten of them gave similar results on Panc1 and BxPC3 pancreatic adenocarcinoma cell lines. A panel of 83 kinases whose inhibition increased gemcitabine-induced apoptosis by 50% or more was also established. Twelve kinases appeared in both panels. A cumulative increase in apoptosis was observed when inhibiting simultaneously several kinases. Such a systematic approach allowed characterization of all kinases involved in pancreatic cancer cell survival and resistance to gemcitabine. Inhibitors of these kinases, used alone or in combination, might improve the treatment of pancreatic adenocarcinoma.—Giroux, V., Iovanna, J., Dagorn, J-C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.


Key Words: apoptosis • pancreatic adenocarcinoma • chemotherapy







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The Federation of American Societies for Experimental Biology.